Expert Consensus on the Clinical Application of Organoid Drug Sensitivity Testing to Guide Precision Treatment of Cancer 公告 2024-12-16 08:46:53 Written By Kym Kilbourne Title: Expert Consensus on the Clinical Application of Organoid Drug Sensitivity Testing to Guide Precision Treatment of Cancer Abstract In the era of precision medicine, the rapid development of targeted and immunotherapy for cancer has led to an increasing demand for personalized and precise drug treatments for patients. Organoid technology, as an emerging functional testing technique, has garnered significant attention due to its ability to preserve the cellular architecture and molecular characteristics of tumor tissues and its high accuracy in predicting patient responses. This expert consensus aims to promote the standardized application of organoid drug sensitivity testing in clinics and provide guidance for clinical treatment. Overview of Organoid Technology Cancer organoids are three-dimensional models cultured from patient tumor tissues ex vivo and are highly similar to the patient's tumor characteristics. They can preserve pathological, molecular features, drug sensitivity, and can be long-term cultured and stably passaged in vitro. Organoid technology provides a new in vitro model for guiding personalized medication in clinics. Types of Drugs for Sensitivity Testing Anticancer drugs can be categorized into cytotoxic drugs (chemotherapeutic agents), targeted therapies, and immunotherapeutic agents. Organoid drug sensitivity testing can be used to assess the sensitivity to chemotherapeutic drugs and most targeted therapies, testing either single drugs or drug combinations. Application Scenarios Organoid drug sensitivity testing is suitable for patients who have failed standard treatments, patients with rare or refractory tumors lacking standard treatment protocols, and patients who may not benefit from recommended guidelines. After obtaining informed consent from patients, organoid culture and drug sensitivity testing can be recommended to provide a reference for their medication selection. Testing Process The process of organoid drug sensitivity testing includes key steps such as patient consent, tumor tissue collection and submission, organoid culture, drug sensitivity testing, and result interpretation. The test report should provide detailed information and key conclusive descriptions to serve as a reference for clinical physicians. Conclusion As a novel in vitro model, the drug sensitivity testing of cancer organoids is a focus of global experts and is actively explored in clinical treatment. Although its guidance for clinical patient medication selection is still in its infancy, with further research and advancements, the application prospects of organoid technology will become increasingly broad. This includes the establishment of large-scale organoid model libraries and patient stratification based on drug sensitivity testing results from organoid model libraries to guide precision treatment. Kym Kilbourne
Expert Consensus on the Clinical Application of Organoid Drug Sensitivity Testing to Guide Precision Treatment of Cancer 公告 2024-12-16 08:46:53 Written By Kym Kilbourne Title: Expert Consensus on the Clinical Application of Organoid Drug Sensitivity Testing to Guide Precision Treatment of Cancer Abstract In the era of precision medicine, the rapid development of targeted and immunotherapy for cancer has led to an increasing demand for personalized and precise drug treatments for patients. Organoid technology, as an emerging functional testing technique, has garnered significant attention due to its ability to preserve the cellular architecture and molecular characteristics of tumor tissues and its high accuracy in predicting patient responses. This expert consensus aims to promote the standardized application of organoid drug sensitivity testing in clinics and provide guidance for clinical treatment. Overview of Organoid Technology Cancer organoids are three-dimensional models cultured from patient tumor tissues ex vivo and are highly similar to the patient's tumor characteristics. They can preserve pathological, molecular features, drug sensitivity, and can be long-term cultured and stably passaged in vitro. Organoid technology provides a new in vitro model for guiding personalized medication in clinics. Types of Drugs for Sensitivity Testing Anticancer drugs can be categorized into cytotoxic drugs (chemotherapeutic agents), targeted therapies, and immunotherapeutic agents. Organoid drug sensitivity testing can be used to assess the sensitivity to chemotherapeutic drugs and most targeted therapies, testing either single drugs or drug combinations. Application Scenarios Organoid drug sensitivity testing is suitable for patients who have failed standard treatments, patients with rare or refractory tumors lacking standard treatment protocols, and patients who may not benefit from recommended guidelines. After obtaining informed consent from patients, organoid culture and drug sensitivity testing can be recommended to provide a reference for their medication selection. Testing Process The process of organoid drug sensitivity testing includes key steps such as patient consent, tumor tissue collection and submission, organoid culture, drug sensitivity testing, and result interpretation. The test report should provide detailed information and key conclusive descriptions to serve as a reference for clinical physicians. Conclusion As a novel in vitro model, the drug sensitivity testing of cancer organoids is a focus of global experts and is actively explored in clinical treatment. Although its guidance for clinical patient medication selection is still in its infancy, with further research and advancements, the application prospects of organoid technology will become increasingly broad. This includes the establishment of large-scale organoid model libraries and patient stratification based on drug sensitivity testing results from organoid model libraries to guide precision treatment. Kym Kilbourne
